Top Markets
Coin of the day
Codex DNA, Inc. Codex DNA, Inc.

Codex DNA, Inc.

DNAY
주식 순위 #28192
Operating in the synthetic biology sector, Codex DNA, Inc. develops,... Operating in the synthetic biology sector, Codex DNA, Inc. develops, manufactures, and sells advanced instruments, reagents, and complementary services. Its primary customer base comprises pharmaceutical firms and academic laboratories worldwide, though it also extends its offerings to government institutions, contract research organizations, and other synthetic biology companies. The company's innovative product portfolio includes the BioXp system, designed to transform digital DNA sequences into usable synthetic DNA, alongside the intuitive BioXp portal, an online platform facilitating DNA sequence design and assembly into chosen vectors. Researchers can also access BioXp kits, which supply essential building blocks and reagents, including the proprietary Gibson Assembly brand, for specific synthetic biology applications. Further support is provided through cloud-based scripts and specialized benchtop reagents for processing products generated by the BioXp system. Moreover, Codex DNA offers Biofoundry Services, allowing clients to commission and receive endpoint-ready BioXp products like genes, clones, cell-free amplified DNA, and variant libraries, in addition to providing short oligo ligation assembly enzymatic DNA synthesis. Established in 2011 and headquartered in San Diego, California, the company rebranded as Codex DNA, Inc. in March 2020, having previously been known as SGI-DNA, Inc.
주가
$1.30
마지막 동기화: 2023-01-03
시가총액
$27.96M
변동 (1일)
8.33%
변동 (1년)
0.00%
국가
US
거래 Codex DNA, Inc. (DNAY)

카테고리

Codex DNA, Inc. (DNAY)의 수익
2026 기준 수익 TTM: 0
Codex DNA, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Codex DNA, Inc.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US